

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of Christine A. WHITE et al.	Examiner: Alana Harris
Confirmation No.  Serial No. 09/436,347	Group Art Unit: 1643
Filed: November 9, 1999	Attorney Docket No.: 27693-01201
For: TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA USING ANTI- CD20 ANTIBODIES (as amended)	

**CONSENT OF ASSIGNEE TO ADDITION OF INVENTOR**  
**UNDER 37 C.F.R. § 1.48(a)(5)**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450


Sir:

Biogen Idec Inc. is the assignee of the entire right, title, and interest to the above-identified application. The assignment from the inventor(s) to Idec Pharmaceuticals Corporation was recorded in the United States Patent and Trademark Office on December 22, 1999, at Reel 010464, Frame 0829. Idec Pharmaceuticals Corporation became Biogen Idec Inc. through a formal name change on November 12, 2003. The name change to Biogen Idec Inc. was recorded the United States Patent and Trademark Office in connection with this application on August 28, 2009, at Reel 023166, Frame 0937.

Biogen Idec Inc., as owner by assignment of the above-identified application, recognize that John G. Curd and Susan Desmond-Hellmann were not named as inventors by error without any deceptive intent. As such, Biogen Idec Inc. hereby consents to the addition of John G. Curd and Susan Desmond-Hellmann as inventors of the above-identified application as amended.

The undersigned, whose titles are supplied below, are authorized to act on behalf of the assignees.

Respectfully submitted,

By:  \_\_\_\_\_

Name: John M. Dunn

Date: November 9, 2009

Title: Executive Vice President, New Ventures

for BIOGEN IDEC INC.